InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, founded in 1981. The company focuses on developing cannabinoid-inspired therapeutics, particularly small-molecule and cannabinoid-derived drug candidates aimed at addressing conditions with significant unmet medical need—especially in dermatology and ophthalmology. From a business perspective, InMed’s model is ...InMed Pharmaceuticals Inc. (NASDAQ: INM) is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, founded in 1981. The company focuses on developing cannabinoid-inspired therapeutics, particularly small-molecule and cannabinoid-derived drug candidates aimed at addressing conditions with significant unmet medical need—especially in dermatology and ophthalmology.
From a business perspective, InMed’s model is typical of early-stage biopharma: it allocates resources to discovery, preclinical work, and clinical trials while building a pipeline that can later support regulatory submissions and commercialization opportunities. The provided description highlights a portfolio anchored by INM-755, a cannabinol-infused topical cream that is progressing through Phase I clinical testing for epidermolysis bullosa. The company also advances other programs across different development stages, including INM-088 for glaucoma (preclinical) and INM-405 for pain relief (pipeline development). In parallel, InMed performs IND-enabling pharmacology and preclinical toxicology research, indicating an ongoing commitment to the non-clinical and regulatory groundwork required to move candidate drugs into human trials.
In terms of products and technology, InMed is associated with “IntegraSyn,” an integrated biosynthesis approach intended to produce pharmaceutical-grade cannabinoids efficiently. This type of platform can influence both the supply chain (how active pharmaceutical ingredients are produced) and overall cost structure (BOM-related considerations such as sourcing, purification, and manufacturing complexity). While precise costs and BOM breakdowns are not provided in the supplied data, companies with proprietary manufacturing/synthesis approaches often seek to improve yield, reduce variability, and support scalability—factors that can affect later-stage manufacturing economics.
Financially, the company’s public-market metrics provided in the source show it is not currently producing sustainable profits (consistent with many development-stage firms), and it likely depends on funding via equity and/or capital markets activity to support trials and ongoing R&D. The data also reflects meaningful cash/working-capital positioning (e.g., a positive working capital figure in the snapshot), which is important for runway during clinical development.
Key people include Eric A. Adams, who has served as President and Chief Executive Officer and a Director since 2016. InMed also participates in research collaborations, such as a partnership with BayMedica Inc. to collaborate on formulation and assessment of novel cannabinoid therapeutics—an approach that can help accelerate development timelines and broaden expertise.
Overall, InMed’s “wishes” as a development-stage company are aligned with progressing candidates through clinical milestones, strengthening its pipeline, and ultimately obtaining regulatory approvals for therapies that can be manufactured at scale and commercialized. Success would likely depend on clinical outcomes, regulatory progress, effective IP and platform execution (including biosynthesis capabilities), and maintaining sufficient funding to support multi-program development.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$4.9M
+7.5%
-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-8.2M
-6.3%
-6.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+34.5%
+44.2%
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-160.2%
+9.5%
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-165.1%
+1.1%
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-7.8M
-11.0%
+45.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-157.1%
-3.3%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
5.5%
-47.2%
+9.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
6.99x
+58.7%
-47.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
